While the mechanisms are complex, the highlights are straightforward: Stimulates collagen production Improves blood supply to injured tissues Reduces inflammatory markers Supports healthy regeneration of muscles, nerves, and blood vessels Helps maintain gut lining integrity In simple terms, BPC-157 tells your body: Hey, lets speed things up a bit, and your cells respond with enthusiasm
And the cherry on top

Owners commonly notice one or more of the following: Limping or lameness: favoring a limb, "toe-touching," or intermittent limping that comes and goes Stiffness after rest: difficulty rising after sleeping, or a slow, stiff first few minutes that loosens with movement Reluctance to jump, climb, or use stairs: hesitating at the car, couch, or staircase they used to handle easily Reduced activity or stamina: shorter walks, less play, or lagging behind on familiar routes Audible joint changes: clicking or popping from a joint, particularly the stifle (knee) Muscle loss: visible thinning of the muscle on one hind limb compared with the other, a sign of chronic underuse Behavioral changes: licking a joint, irritability when a limb is handled, or a drop in overall mood tied to discomfort A sudden non-weight-bearing lameness the dog will not put any weight on a leg warrants prompt veterinary attention rather than watchful waiting, as it can indicate an acute cruciate rupture or fracture

Under the WADA 2024 Prohibited List (Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics), IGF-1 and its analogs, including IGF-1 LR3, are prohibited in-competition and out-of-competition
This raises questions about cost-effectiveness and access, but if priced reasonably or if generics eventually become available, we may see a broad shift where anti-obesity pharmacotherapy (especially GLP-1/GIP-based) is as commonplace as antihypertensive or lipid-lowering therapy